GGrantIndex
← Leaderboards

Michael G Roth

University Of Texas Sw Med Ctr/Dallas

$12,768,649
Attributed
$16,860,616
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY200720
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$16,860,616 · 9

By mechanism

R01$5,920,991 · 4
RC2$4,345,625 · 1
P01$3,383,024 · 2
U01$2,800,374 · 1
S10$410,602 · 1

Top collaborators

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “High Throughput Screening

Research focus

High Throughput ScreeningLibrariesMolecularCellsResearch StudyPathway InteractionsPharmaceutical PreparationsStructureBaseLaboratoriesResponseGrowthGene ExpressionSmall MoleculeToxic EffectInhibitor/AntagonistMalignant NeoplasmsResistanceBiochemicalAffectSmall Interfering RnaPreventCellular BiologyMutation

Grant awards (31)

HTS for discovery of inhibitors of the centrosome-independent mitotic spindle machinery$370,575
R01 · FY2020 · CA · contact PI
HTS for discovery of inhibitors of the centrosome-independent mitotic spindle machinery$359,457
R01 · FY2019 · CA · contact PI
HTS for discovery of inhibitors of the centrosome-independent mitotic spindle machinery$370,575
R01 · FY2018 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$706,409
U01 · FY2016 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$706,409
U01 · FY2015 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$685,218
U01 · FY2014 · CA · contact PI
Novel Inhibitors of Viral Replication$401,322
R01 · FY2014 · AI · contact PI
Using Chemical Biology to Interfere with the Influenza Virus Life Cycle$393,525
R01 · FY2014 · AI · contact PI
Lung cancer oncogenotype-selective drug target discovery$702,338
U01 · FY2013 · CA · contact PI
Novel Inhibitors of Viral Replication$377,242
R01 · FY2013 · AI · contact PI
Using Chemical Biology to Interfere with the Influenza Virus Life Cycle$369,914
R01 · FY2013 · AI · contact PI
A Concerted Attack on Patient Specific Oncogenic Vulnerabilities in Lung Cancer$595,625
RC2 · FY2012 · CA · contact PI
Using Chemical Biology to Interfere with the Influenza Virus Life Cycle$401,105
R01 · FY2012 · AI · contact PI
Novel Inhibitors of Viral Replication$401,105
R01 · FY2012 · AI · contact PI
High-throughput Screening Core$682,760
P01 · FY2011 · CA · contact PI
Novel Inhibitors of Viral Replication$400,455
R01 · FY2011 · AI · contact PI
Using Chemical Biology to Interfere with the Influenza Virus Life Cycle$400,455
R01 · FY2011 · AI · contact PI
A Concerted Attack on Patient Specific Oncogenic Vulnerabilities in Lung Cancer$1,644,663
RC2 · FY2010 · CA · contact PI
High-throughput Screening Core$703,204
P01 · FY2010 · CA · contact PI
Using Chemical Biology to Interfere with the Influenza Virus Life Cycle$419,125
R01 · FY2010 · AI · contact PI
Novel Inhibitors of Viral Replication$419,125
R01 · FY2010 · AI · contact PI
Echo 555 Acoustical Droplet Ejection System for High-throughput Screening$410,602
S10 · FY2010 · RR · contact PI
A Concerted Attack on Patient Specific Oncogenic Vulnerabilities in Lung Cancer$2,105,337
RC2 · FY2009 · CA · contact PI
High-throughput Screening Core$689,626
P01 · FY2009 · CA · contact PI
High-throughput Screening Core$568,157
P01 · FY2008 · CA · contact PI
High-throughput Screening Core$739,277
P01 · FY2007 · CA · contact PI
RECOGNITION AND SORTING OF GLYCOPROTEINS$287,200
R01 · FY2002 · GM
Core--High throughput screening$0
P01 · FY2002 · CA
Molecular targets of novel cytotoxic agents$0
P01 · FY2002 · CA
RECOGNITION AND SORTING OF GLYCOPROTEINS$278,923
R01 · FY2001 · GM
RECOGNITION AND SORTING OF GLYCOPROTEINS$270,888
R01 · FY2000 · GM